A few points off the top of my head.
Share price - good reentry level - relatively small position at this stage
Mithra
Covid-19 demand
Expectation of FDA approvals
Aussie dollar level
Strategy of building niche branded product range
Election year....positive policies on imports
rationalisation of generic product range....more profitable
Still expect some impact of D of J Price fixing and associated suits by States......but less significant than the market expectations that drove down the share price initially but out weighed by good news to come.
Growth in contract research.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M | |||
| Open | High | Low | Value | Volume |
| $5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 810 | $5.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.15 | 2033 | 2 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |